Correction: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program (Clinical Cancer Research (2015) 21 (819-832) DOI: 10.1158/1078-0432.CCR-14-2572);Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 819-832

  Smith, Malcolm A ^a   Reynolds, C Patrick ^b   Kang, Min H ^b   Kolb, E Anders ^c   Gorlick, Richard ^d   Carol, Hernan ^e   Lock, Richard B ^e   Keir, Stephen T ^f   Maris, John M ^g   Billups, Catherine A ^h   Lyalin, Dmitry ⁱ   Kurmasheva, Raushan T ⁱ   Houghton, Peter J ⁱ  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^d CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^e CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; N,N DIMETHYLACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SOLUTOL HS 15; TALAZOPARIB; TEMOZOLOMIDE; TOPOTECAN; ANTINEOPLASTIC AGENT; DACARBAZINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHILDHOOD CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; GLIOBLASTOMA; IC50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MOUSE; MOUSE MODEL; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; RHABDOMYOSARCOMA; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BONE TUMOR; DRUG SCREENING; HUMAN; IMMUNOBLOTTING; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICE, SCID; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923164096     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2920     Document Type: Erratum

References (42)

1. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13: 411-24.
2. Cistulli C, Lavrik OI, Prasad R, Hou E, Wilson SH. AP endonuclease and poly(ADP-ribose) polymerase-1 interact with the same base excision repair intermediate. DNA Repair 2004; 3: 581-91.
3. Horton JK, Wilson SH. Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res 2013; 11: 13-8.
4. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012; 84: 137-46.
5. Das BB, Huang SY, Murai J, Rehman I, Ame JC, Sengupta S, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 2014; 42: 4435-49.
6. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-23.
7. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013; 71: 1191-9.
8. Su JM, Thompson PA, Adesina A, Li XN, Kilburn LB, Onar-Thomas A, et al. A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: a pediatric brain tumor consortium report. J Clin Oncol 2013; 31:(suppl; abstr 2036).
9. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011; 71: 5626-34.
10. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104: 750-5.
11. Middleton M, Friedberg EC, Hamid O, Daud A, Plummer R, Schuster R, et al. Veliparib (ABT-888) plus temozolomide versus temozolomide alone: efficacy and safety in patients with metastatic melanoma in a randomized double-blind placebo-controlled trial. 24: 1022-1023. Pigment Cell Melanoma Res 2011; 24: 1022-3.
12. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
13. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
14. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2014 Nov 3. [Epub ahead of print].
15. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14: 882-92.
16. De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, et al. First-in-human trialofnovel oral PARP inhibitor BMN 673inpatients with solid tumors J Clin Oncol 2013; 31:(suppl; abstr 2580).
17. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-5.
18. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012; 72: 1608-13.
19. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010; 16: 4527-31.
20. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-99.
21. Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 2012; 10: 360-8.
22. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014; 13: 433-43.
23. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, et al. Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014; 349: 408-16.
24. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013; 19: 5003-15.
25. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, et al. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2015; 62: 91-8.
26. Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-97.
27. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56: 239-49.
28. Sebaugh JL Guidelines for accurate EC50/IC50 estimation. Pharmaceut Statist 2010; 10: 128-34.
29. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-40.
30. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-14.
31. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: 783-90.
32. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program. Mol Cancer Ther 2010; 9: 101-12.
33. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC cancer 2014; 14: 813.
34. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54: 334-41.
35. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010; 9: 168-78.
36. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26: 186-97.
37. Newman RE, Soldatenkov VA, Dritschilo A, Notario V. Poly(ADP-ribose) polymerase turnover alterations donot contributeto PARP overexpression in Ewing's sarcoma cells. Oncol Rep 2002; 9: 529-32.
38. Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V. Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 1999; 18: 3954-62.
39. Blumenthal DT, Rankin CJ, Stelzer K, Schulman S, Sloan A, Rushing EJ, et al. SWOG S0001: a phase III study of radiation therapy (RT) and O6-benzylguanine (O6-BG) plus BCNU versus RT and BCNU alone for newly diagnosed glioblastoma multiforme (GBM) and gliosarcoma. Neuro-Oncology 2006; 8: 438 (abstr TA-04).
40. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007; 25: 2540-5.
41. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, et al. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 2008; 98: 1614-8.
42. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.